Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease neurofibromatosis 2
Symptom C0027859|vestibular schwannoma
Sentences 11
PubMedID- 24335931 Ipsilateral cochlear implantation after cochlear nerve preserving vestibular schwannoma surgery in patients with neurofibromatosis type 2.
PubMedID- 21817944 Objectives: to discuss our management strategy of vestibular schwannoma in patients with neurofibromatosis type 2 (nf2).
PubMedID- 24436903 Six patients had neurofibromatosis type 2 (nf2) with bilateral vestibular schwannomas and meningiomas, and the four others had aggressive recurrent meningiomas.
PubMedID- 24311643 Methods: we conducted a single-institution, prospective, 2-stage, open-label phase ii study to estimate the response rate to everolimus in neurofibromatosis type 2 (nf2) patients with progressive vestibular schwannoma (vs).
PubMedID- 25537817 The aim of this study was to evaluate the cochlear implant (ci) performances in neurofibromatosis type 2 (nf2) patients with bilateral vestibular schwannoma (vs) and in patients with sporadic vs in the only or better hearing ear.
PubMedID- 26287269 Factors influencing the growth rate of vestibular schwannoma in patients with neurofibromatosis type 2.
PubMedID- 25567352 Phase ii study of mtorc1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.
PubMedID- 20848106 Furthermore, tumour location and patient age may point to a familial tumour syndrome as in the case of neurofibromatosis type 2 (nf2) with typical bilateral vestibular schwannoma in young age.
PubMedID- 22844108 This single-institution phase ii study was performed to estimate the response rate to lapatinib in neurofibromatosis type 2 (nf2) patients with progressive vestibular schwannoma (vs).
PubMedID- 22805104 Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
PubMedID- 26108240 Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage.

Page: 1